The adult mammalian heart bears limited regenerative capacity, resulting in the irreversible loss of cardiomyocytes post-cardiac injury, and often culminating in end-stage heart failure. Cardiomyocyte ...
Heart failure is the terminal stage of various cardiovascular diseases, usually characterized by pathological myocardial hypertrophy. So far, the pathogenesis of heart failure is not fully understood.
In vivo generation of transient FAPCAR T cells improves cardiac function after injury. CAR T therapy, a “living drug,” traditionally involves isolation and purification of T cells outside the body.
The most comprehensive cell "atlas" of the developing human heart to date was crafted using cutting-edge technology and includes never-before-seen cell types. When you purchase through links on our ...
(RTTNews) - BioCardia, Inc. (BCDA), a clinical-stage biotechnology company specializing in cellular therapies for cardiovascular disease, on Thursday announced that the first patient has been enrolled ...
Secretome Therapeutics, a pioneering company in the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the ...
People who receive stem cell therapy within a week of their first heart attack have nearly a 60 per cent lower risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback